Cureus | ALBI-RT: A Novel Radiation Therapy Specific Hepatotoxicity Prediction Model for Hepatocellular Carcinoma Patients

ALBI-RT: A Novel Radiation Therapy Specific Hepatotoxicity Prediction Model for Hepatocellular Carcinoma Patients



Abstract

Objectives: An unmet need in radiation treatment (RT) of hepatocellular cancer (HCC) is
objective prediction models that aid in appropriate patient selection for safe treatment. Recent
studies have suggested the albumin-bilirubin (ALBI) grade system may predict for hepatotoxicity;
however, the original ALBI grades were not optimized to predict survival after RT. We propose a
novel analysis of the ALBI equation, designated ALBI-RT, to assess hepatotoxicity risk in HCC
patients after RT.


Methods: We retrospectively reviewed the charts of 47 consecutive HCC patients treated with
SBRT (n = 21) and hypofractionated proton therapy (n = 26) from 2013-2016. Raw ALBI values and
Child-Pugh (CP) scores were calculated from albumin and bilirubin data. Any patient deaths were
recorded, and assessed for association with radiation induced liver disease (RILD). Raw ALBI was
assessed as a continuous variable to perform ROC analyses to identify cutoffs for overall survival
(OS) and RILD-specific survival (RILD-SS) that maximized the Youden index of ROC accuracy.
Dichotomization of the ROC for RILD-SS resulted in ALBI-RT. Univariate predictors of OS and
RILD-SS were evaluated using Cox proportional hazard regression to determine hazard ratios (HR)
and Chi-squared p values.


Results: Patient cohort median age was 67 years (43-89) with 62% CP-A and 38% CP-B/C.
Median follow-up and OS was 13 months and 10 months, respectively. There were 18 deaths with
6 ascribed to RILD. ROC analysis based on raw ALBI identified an OS cutoff at -2.00 (AUC=0.68,
p=0.04) with a sensitivity and specificity of 67%. ROC analysis for RILD-SS had an increased
sensitivity to 100% and specificity of 71% with an identified raw ALBI cutoff at -1.70 (AUC=0.94,
p=0.008). We defined ALBI-RT grades as: A <-1.70 (n=29) and B = -1.70 (n=18). On univariate
analysis for OS, raw ALBI as a continuous variable (HR 3.0, p=0.02) and to a lesser degree ALBI-RT
Grade B (HR 2.4, p=0.06) performed similarly to traditional ALBI grade (HR 3.0, p=0.01), and CP
score (HR 1.4, p=0.03). Conversely, for RILD-SS, univariate analysis revealed that raw ALBI as a
continuous variable (HR 25.1, p=0.01) and ALBI-RT Grade B (HR 9.9, p=0.04) were associated with
higher average increases in relative risk of radiation-related hepatotoxicity than traditional ALBI
grade (HR 5.8, p=0.02) and CP score (HR 2.3, p=0.003).


Conclusions: ALBI-RT is a promising novel metric that may have a larger effect size when
predicting RILD related death after RT for HCC than both CP and conventional ALBI grades in this
patient cohort. It has potential utility in the pre-treatment assessment of HCC patients, with a
cutoff of = -1.70 predicting death from RILD. Future prospective evaluation and validation in
independent data sets will strengthen the generalizability and utility of ALBI-RT.

Related content

abstract
non-peer-reviewed

ALBI-RT: A Novel Radiation Therapy Specific Hepatotoxicity Prediction Model for Hepatocellular Carcinoma Patients


Author Information

Smith Apisarnthanarax Corresponding Author

Radiation Oncology, University of Washington

Stephanie Schaub

Radiation Oncology, University of Washington, Seattle, USA

Stephen R. Bowen

Radiation Oncology, University of Washington Medical Center, Seattle, USA

Tobias Chapman

Department of Radiation Oncology, University of Washington

Matthew Nyflot

Radiation Oncology, University of Washington, Seattle, USA


PDF Share